Schizoaffective Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major schizoaffective disorder markets are expected to exhibit a CAGR of 2.21% during 2024-2034.
The schizoaffective disorder market has been comprehensively analyzed in IMARC's new report titled "Schizoaffective Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Schizoaffective disorder refers to a chronic mental health illness characterized by a combination of symptoms of schizophrenia and mood conditions, such as bipolar or major depressive diseases. It is considered a complex and relatively rare psychiatric ailment that affects a person's thoughts, emotions, and behavior. People suffering from this condition generally experience indications of schizophrenia, including hallucinations, delusions (holding false beliefs), disorganized thinking and speech, impaired social functioning, etc. These symptoms are often accompanied by periods of significant mood disturbance, such as elevated or low mood, increased energy, depression, persistent sadness, loss of interest or pleasure in activities, etc. The diagnosis of this ailment is mainly based on a comprehensive clinical interview to gather information about the patient's indications, medical history, and family history of mental health conditions. A healthcare professional will further assess the underlying symptoms against the diagnostic criteria guided by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) to validate a diagnosis. Various other diagnostic tests, like blood workup, toxicology screening, urine analysis, etc., are also utilized to support the diagnosis of the disease.
The rising cases of brain abnormalities causing structural and functional defects in certain neurological regions, such as the prefrontal cortex, hippocampus, basal ganglia, etc., are primarily driving the schizoaffective disorder market. In addition to this, the increasing prevalence of genetic variations that may affect the balance of neurotransmitters responsible for the regulation of mood and perception is also propelling the market growth. Furthermore, the widespread adoption of effective drugs, including antipsychotics, selective serotonin reuptake inhibitors, benzodiazepines, etc., to manage the symptoms of the disease is creating a positive outlook for the market. Apart from this, the emerging popularity of cognitive behavioral therapy, which works by identifying and changing negative thought patterns and emotions in patients to develop coping skills, alleviate stress, and improve overall functioning, is also acting as another significant growth-inducing factor. Moreover, the inflating application of mindfulness-based interventions on account of their several benefits, like enhancing self-awareness, increasing acceptance of internal experiences, and boosting emotional regulation, is expected to drive the schizoaffective disorder market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the schizoaffective disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for schizoaffective disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the schizoaffective disorder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the schizoaffective disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the schizoaffective disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current schizoaffective disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical trial results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the schizoaffective disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the schizoaffective disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the schizoaffective disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of schizoaffective disorder across the seven major markets?
What is the number of prevalent cases (2018-2034) of schizoaffective disorder by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of schizoaffective disorder by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with schizoaffective disorder across the seven major markets?
What is the size of the schizoaffective disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of schizoaffective disorder?
What will be the growth rate of patients across the seven major markets?
Schizoaffective Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for schizoaffective disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the schizoaffective disorder market?
What are the key regulatory events related to the schizoaffective disorder market?
What is the structure of clinical trial landscape by status related to the schizoaffective disorder market?
What is the structure of clinical trial landscape by phase related to the schizoaffective disorder market?
What is the structure of clinical trial landscape by route of administration related to the schizoaffective disorder market?
The schizoaffective disorder market has been comprehensively analyzed in IMARC's new report titled "Schizoaffective Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Schizoaffective disorder refers to a chronic mental health illness characterized by a combination of symptoms of schizophrenia and mood conditions, such as bipolar or major depressive diseases. It is considered a complex and relatively rare psychiatric ailment that affects a person's thoughts, emotions, and behavior. People suffering from this condition generally experience indications of schizophrenia, including hallucinations, delusions (holding false beliefs), disorganized thinking and speech, impaired social functioning, etc. These symptoms are often accompanied by periods of significant mood disturbance, such as elevated or low mood, increased energy, depression, persistent sadness, loss of interest or pleasure in activities, etc. The diagnosis of this ailment is mainly based on a comprehensive clinical interview to gather information about the patient's indications, medical history, and family history of mental health conditions. A healthcare professional will further assess the underlying symptoms against the diagnostic criteria guided by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) to validate a diagnosis. Various other diagnostic tests, like blood workup, toxicology screening, urine analysis, etc., are also utilized to support the diagnosis of the disease.
The rising cases of brain abnormalities causing structural and functional defects in certain neurological regions, such as the prefrontal cortex, hippocampus, basal ganglia, etc., are primarily driving the schizoaffective disorder market. In addition to this, the increasing prevalence of genetic variations that may affect the balance of neurotransmitters responsible for the regulation of mood and perception is also propelling the market growth. Furthermore, the widespread adoption of effective drugs, including antipsychotics, selective serotonin reuptake inhibitors, benzodiazepines, etc., to manage the symptoms of the disease is creating a positive outlook for the market. Apart from this, the emerging popularity of cognitive behavioral therapy, which works by identifying and changing negative thought patterns and emotions in patients to develop coping skills, alleviate stress, and improve overall functioning, is also acting as another significant growth-inducing factor. Moreover, the inflating application of mindfulness-based interventions on account of their several benefits, like enhancing self-awareness, increasing acceptance of internal experiences, and boosting emotional regulation, is expected to drive the schizoaffective disorder market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the schizoaffective disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for schizoaffective disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the schizoaffective disorder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the schizoaffective disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the schizoaffective disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current schizoaffective disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical trial results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the schizoaffective disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the schizoaffective disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the schizoaffective disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of schizoaffective disorder across the seven major markets?
What is the number of prevalent cases (2018-2034) of schizoaffective disorder by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of schizoaffective disorder by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with schizoaffective disorder across the seven major markets?
What is the size of the schizoaffective disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of schizoaffective disorder?
What will be the growth rate of patients across the seven major markets?
Schizoaffective Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for schizoaffective disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the schizoaffective disorder market?
What are the key regulatory events related to the schizoaffective disorder market?
What is the structure of clinical trial landscape by status related to the schizoaffective disorder market?
What is the structure of clinical trial landscape by phase related to the schizoaffective disorder market?
What is the structure of clinical trial landscape by route of administration related to the schizoaffective disorder market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SCHIZOAFFECTIVE DISORDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SCHIZOAFFECTIVE DISORDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SCHIZOAFFECTIVE DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 SCHIZOAFFECTIVE DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SCHIZOAFFECTIVE DISORDER - UNMET NEEDS
10 SCHIZOAFFECTIVE DISORDER - KEY ENDPOINTS OF TREATMENT
11 SCHIZOAFFECTIVE DISORDER - MARKETED PRODUCTS
11.1 List of Schizoaffective Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Invega (Paliperidone) - Johnson & Johnson
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SCHIZOAFFECTIVE DISORDER - PIPELINE DRUGS
12.1 List of Schizoaffective Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 LYN005 - Lyndra Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SCHIZOAFFECTIVE DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SCHIZOAFFECTIVE DISORDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SCHIZOAFFECTIVE DISORDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Schizoaffective Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Schizoaffective Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Schizoaffective Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Schizoaffective Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Schizoaffective Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Schizoaffective Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Schizoaffective Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Schizoaffective Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Schizoaffective Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Schizoaffective Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Schizoaffective Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Schizoaffective Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Schizoaffective Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Schizoaffective Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Schizoaffective Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Schizoaffective Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Schizoaffective Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Schizoaffective Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Schizoaffective Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Schizoaffective Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Schizoaffective Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Schizoaffective Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Schizoaffective Disorder - Access and Reimbursement Overview
16 SCHIZOAFFECTIVE DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SCHIZOAFFECTIVE DISORDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SCHIZOAFFECTIVE DISORDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SCHIZOAFFECTIVE DISORDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SCHIZOAFFECTIVE DISORDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SCHIZOAFFECTIVE DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 SCHIZOAFFECTIVE DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SCHIZOAFFECTIVE DISORDER - UNMET NEEDS
10 SCHIZOAFFECTIVE DISORDER - KEY ENDPOINTS OF TREATMENT
11 SCHIZOAFFECTIVE DISORDER - MARKETED PRODUCTS
11.1 List of Schizoaffective Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Invega (Paliperidone) - Johnson & Johnson
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SCHIZOAFFECTIVE DISORDER - PIPELINE DRUGS
12.1 List of Schizoaffective Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 LYN005 - Lyndra Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SCHIZOAFFECTIVE DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SCHIZOAFFECTIVE DISORDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SCHIZOAFFECTIVE DISORDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Schizoaffective Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Schizoaffective Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Schizoaffective Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Schizoaffective Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Schizoaffective Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Schizoaffective Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Schizoaffective Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Schizoaffective Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Schizoaffective Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Schizoaffective Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Schizoaffective Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Schizoaffective Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Schizoaffective Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Schizoaffective Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Schizoaffective Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Schizoaffective Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Schizoaffective Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Schizoaffective Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Schizoaffective Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Schizoaffective Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Schizoaffective Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Schizoaffective Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Schizoaffective Disorder - Access and Reimbursement Overview
16 SCHIZOAFFECTIVE DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SCHIZOAFFECTIVE DISORDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SCHIZOAFFECTIVE DISORDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
